ClinicalTrials.Veeva

Menu
E

EP-SOGO Co., Ltd. | Nagoya City University Hospital

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dexamethasone
Daratumumab
Lenalidomide
Elranatamab
Bortezomib
Pomalidomide
Guselkumab
JNJ-77242113
JNJ-73763989
Teclistamab

Parent organization

This site is a part of EP-SOGO Co., Ltd.

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

48 of 55 total trials
Locations recently updated

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-c...

Enrolling
Multiple Myeloma
Drug: Cilta-cel

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

The purpose of this study is to compare the efficacy of JNJ-68284528 (ciltacabtagene autoleucel \[cilta-cel\]) with standard therapy, either Pomalido...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Bortezomib

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administratio...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at th...

Active, not recruiting
Multiple Myeloma
Drug: Talquetamab

The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic pso...

Enrolling
Generalized Pustular Psoriasis
Erythrodermic Psoriasis
Drug: JNJ-77242113

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The main aims of this 3-part study are as follows:Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occu...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Modakafusp alfa

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Bendamustine

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and...

Enrolling
Generalized Pustular Psoriasis
Erythrodermic Psoriasis
Drug: TAK-279

The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with p...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Teclistamab

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characteriz...

Enrolling
Multiple Myeloma
Drug: Daratumumab
Drug: Teclistamab

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Ustekinumab
Drug: Guselkumab Dose 3

The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 in participants with relapsed or refractory T-...

Enrolling
Relapsed or Refractory T-cell Lymphomas
Drug: BMS-986369

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Pfizer logo
Celgene logo
Bayer logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Loxo Oncology logo
Bristol-Myers Squibb (BMS) logo
Gilead Sciences logo
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems